Thi Thu Thao Nguyen

Thi Thu Thao Nguyen

Auto-generated profile, based on publicly available information

Thi Thu Thao Nguyen

Computational Sciences Center of Excellence, Genentech, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in EMBO Reports
Verified
Journal Article
Open access
PHPatricia Himmels
Patricia Himmels
TNThi Thu Thao Nguyen
Thi Thu Thao Nguyen
MMMaresa Caunt Mitzner
Maresa Caunt Mitzner
AAAlfonso Arrazate
Alfonso Arrazate
SYStacey Yeung
Stacey Yeung
WYWeilan Ye
Weilan Ye
Preclinical and clinical studies demonstrate that T cell-dependent bispecific antibodies (TDBs) induce systemic changes in addition to tumor killing, leading to adverse events. Here, we report an in-depth characterization of acute responses to TDBs in tumor-bearing mice. Contrary to modest changes in tumors, rapid and substantial lymphocyte accumulation and endothelial cell (EC) activation occur around large blood vessels in normal organs including the liver. We hypothesize that organ-specific ECs may account for the differential responses in normal tissues and tumors, and we identify a list of genes selectively upregulated by TDB in large liver vessels. Using one of the genes as an example, we demonstrate that CD9 facilitates ICAM-1 to support T cell-EC interaction in response to soluble factors released from a TDB-mediated cytotoxic reaction. Our results suggest that multiple factors may cooperatively promote T cell infiltration into normal organs as a secondary response to TDB-mediated tumor killing. These data shed light on how different vascular beds respond to cancer immunotherapy and may help improve their safety and efficacy.

11 June 2026 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AMAmanda R. Moore
Amanda R. Moore
BBBrian Biehs
Brian Biehs
NKNoelyn Kljavin
Noelyn Kljavin
TNThi Thu Thao Nguyen
Thi Thu Thao Nguyen
ASAkansha Shah
Akansha Shah
FSFrederic J. de Sauvage
Frederic J. de Sauvage

22 May 2026 in Science Advances
Verified
Journal Article
Open access
YKYvonne T. Kschonsak
Yvonne T. Kschonsak
WLWei-Ching Liang
Wei-Ching Liang
JCJoyce Chan
Joyce Chan
DKDavid Kan
David Kan
TNThao Nguyen
Thao Nguyen
JKJames T. Koerber
James T. Koerber
Enhancing the specificity of oncogenic pathway inhibition in cancer cells improves both efficacy and tolerability of anticancer therapies. Hyperactivated Wnt signaling is a key driver in cancers such as colorectal cancer and pancreatic ductal adenocarcinoma, but its direct inhibition is limited by severe toxicities due to the importance of Wnt signaling in normal tissues, particularly the gut and bone. To address this challenge, we designed bispecific antibodies that selectively target surface proteins of oncogenic signaling pathways in tumor cells while sparing normal cells. Using single-cell technologies, we identified tumor-specific receptors, including tumor-associated calcium signal transducer 2 (TROP2), which are absent in cells reliant on Wnt signaling. Our TROP2-targeted anti-Frizzled bispecific antibody effectively inhibited Wnt signaling in preclinical models with minimal effect on normal intestinal tissue. Expanding this approach, we developed tumor-targeted, toxicity-sparing bispecific antibodies against fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR). This work establishes a framework for designing targeted therapeutics that minimize cell type–specific toxicities in cancer and other diseases.